Biochem Biophys Res Commun 291:13021308 Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, Sitagliptin 036 Study Group (2007) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
However, safety depends on: Following the recommended dosage Avoiding unnecessary overuse Consulting a healthcare professional if you have a medical condition Daily use should always be moderate and consistent, not excessive
Over 8,000 patients treated Five systems that shape how you age
The neurological complications of diabetes are multifaceted, encompassing cerebrovascular disease and acute metabolic crises such as ketoacidotic, hyperosmolar hyperglycemic, and hypoglycemic coma
Patients starting semaglutide or other GLP-1 therapies should continue monitoring their lipid panels with their primary care physician, as baseline medications may require adjustment based on changing cholesterol levels
Dropped 18 pounds without touching a treadmill
